Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is essential for EBV episome maintenance, replication, and transcription. These effects are mediated by EBNA1 binding to cognate oriP DNA, which comprise 20 imperfect copies of a 30-bp dyad symmetry enhancer and an origin for DNA replication. To identify cell proteins essential for these EBNA1 functions, EBNA1 associated cell proteins were immune precipitated and analyzed by liquid chromatography-tandem mass spectrometry. Nucleolin (NCL) was identified to be EBNA1 associated. EBNA1's N-terminal 100 aa and NCL's RNA-binding domains were critical for EBNA1/NCL interaction. Lentivirus shRNA-mediated NCL depletion substantially reduced EBNA1 recruitment to oriP DNA, EBNA1-dependent transcription of an EBV oriP luciferase reporter, and EBV genome maintenance in lymphoblastoid cell lines. NCL RNA-binding domain K 429 was critical for ATP and EBNA1 binding. NCL overexpression increased EBNA1 binding to oriP and transcription, whereas NCL K 429 A was deficient. Moreover, NCL silencing impaired lymphoblastoid cell line growth. These experiments reveal a surprisingly critical role for NCL K429 in EBNA1 episome maintenance and transcription, which may be a target for therapeutic intervention.
pstein-Barr virus (EBV) was discovered in cultures of Burkitt lymphoma (BL) cells, an endemic African pediatric B-cell lymphoma. EBV is now also implicated in causation of B-and NKT-cell proliferative diseases, Hodgkin disease, nasopharyngeal carcinoma, and antral gastric carcinomas (for reviews, see ref. 1) . Consistent with these oncogenic effects, EBV infection of primary human B lymphocytes causes continuous lymphoblastoid cell proliferation (LCLs), in vitro, and in patients with deficient T-cell immune responses. EBV-transformed B-cell growth requires five EBV nuclear antigen (EBNA) proteins, two integral membrane proteins (LMPs), and may also be affected by EBV nonproteincoding small RNAs (2) .
EBNA1 is the only EBV protein expressed in all EBV infected cells and is essential for EBV episome replication, enhanced transcription, and postmitotic segregation to progeny cells (3) (4) (5) (6) . Most EBNA1 effects are mediated by EBNA1 cognate sequencespecific binding to 20 copies of a 30-bp family of repeats (FR), which mediate EBNA1 enhanced transcription (7) (8) (9) , and to four sites in a dyad symmetry (DS), which is an origin for cell S-phase EBV episome replication. EBNA1 amino acids 387-394 interact with USP7 to destabilize p53 and with casein kinase 2 (CK2) to trigger PML ubiquitylation and degradation (10) , whereas EBNA1 residues that are important for enhanced transcription overlap with residues that are important for EBV genome segregation to progeny cells (11, 12) . Dimerization of EBNA1 N-terminal amino acids 65-89 through zinc is important for enhanced transcription (13) , and arginine-glycine repeat amino acids 33-53 and 325-376 are important for EBV episome segregation to progeny cells (12) . CTCF binding to an EBV promoter control region affects EBNA1-dependent transcription (14) . Bromodomain protein 4 (Brd4) and nucleosome assembly protein 1 (NAP1) are also implicated in EBNA1-mediated episome transcription (15, 16) . The experiments described here were undertaken to identify an EBNA1-interacting cell protein that may be critical for EBNA1 effects in episome maintenance or transcription.
Results NCL Is EBNA1 Associated. M2 flag epitope specific antibodyconjugated Sepharose beads were used to immune precipitate (IP) EBNA1 from flag-tagged EBNA1 (FEBNA1) converted, EBV(-), BJAB cells. BJAB-FEBNA1 express slightly more EBNA1 than IB4 LCLs or AKATA EBV(+) BL cells (Fig. 1A) . Immune precipitated FEBNA1 and associated cell proteins were separated by SDS/PAGE, stained by Coomassie blue, and identified by liquid chromatography-tandem mass spectrometry (LC-MS/ MS) (Fig. 1B) as nucleolin (NCL), 60S ribosome RPL4, and Histone 1.5 (Fig. 1B) .
NCL was further investigated because of its roles in nuclear shuttling, ribosomal rRNA biogenesis, genotoxic stress, histone chaperoning, and similarity to EBNA1 as a substrate for casein kinase 2 (CK2) and p34 cdc2 (17) . Human NCL's N-terminal third is principally composed of aspartic and glutamic acids, followed by occasional basic or hydrophobic residues, four predicted RNA binding domains, and C-terminal RGG repeats (18) . NCL's four RNA recognition motifs (RRM 1-4) interact with stem-loop Significance Epstein-Barr Virus (EBV) genome persistence and expression in human cells can result in human lymphocyte or epithelial cell malignancies. EBV genome persistence and gene expression depends on the EBV encoded Epstein-Barr virus nuclear antigen 1 (EBNA1) protein binding to cognate sites in EBV episomes. Search for a cell protein necessary for EBNA1 interaction with EBV episomes identified a low-level nucleolin (NCL) association with EBNA1. Despite low-level stable association, NCL shRNA knockdowns revealed wild-type NCL, but not an NCL ATP binding site point mutant to be critical for EBNA1 binding to EBV episomes, transcription, and genome maintenance. These experiments identify NCL and NCL K429 as potential targets for inhibition of EBNA1's role in EBV oncogenesis.
RNAs implicated in prerRNA processing (19) . NCL's C-terminal RGG repeats can interact with proteins or nucleic acids (20, 21) . NCL is similar to the facilitates chromatin transcription complex in histone chaperoning and collaboration with chromatin remodeling complexes in regulating RNA polymerase I or II (18, 22, 23) or DNA virus transcription (24) (25) (26) . We therefore investigated whether NCL is important for EBNA1 interaction with oriP in mediating EBV genome persistence, replication, or transcription.
Notably, NCL was expressed at similar levels in primary B cells and LCLs (Fig. S1 ). Approximately 2% of endogenous NCL or FEBNA1 immune precipitated with FEBNA1 or NCL, consistent with a 2% stable NCL and EBNA1 association. Neither protein precipitated with control IgG (Fig. 1C) . Because EBNA1 and NCL can bind RNA, we evaluated whether RNA or DNA mediate EBNA1 interaction with NCL, by comparing NCL and EBNA1 coimmune precipitation from IB4 LCL lysates with or without DNase and RNase pretreatment (Fig. 1D) . Although the same level of DNase and RNase treatment degraded DNA and RNA (Fig. S1B ), EBNA1 and NCL coimmune precipitated at similar levels with or without DNase and RNase pretreatment, consistent with their association being mediated by protein/ protein interaction. However, we cannot exclude the possibility that RNA or DNA may contribute to NCL interaction with EBNA1. NCL and nucleophosmin (NPM) 1 consistently interacted at low levels (27) . Notably, EBNA1 did not coimmune precipitate with NPM1 (Fig. 1D ).
EBNA1 Amino Acids 1-100 and NCL RNA Binding Domains Are Essential for Interaction. Residues necessary for EBNA1 and NCL interaction were first defined using FEBNA1, FEBNA1Δ1-377 or FEBNA1Δ100-377, and GFP-NCL. FEBNA1, FEBNA1Δ1-377, or FEBNA1Δ100-377 were coexpressed with GFP-NCL in BJAB cells and immune precipitated with Flag antibody. Approximately 0.5-1% of GFP-NCL associated with FEBNA1 or FEBNA1Δ100-377, but did not associate with FEBNA1Δ1-377 (Fig. 1E) , indicating that FEBNA1 residues within 1-99 are critical for NCL association. A reciprocal experiment identified FNCL residues critical for FNCL, ΔN, ΔC, or Δ RNA binding domain (ΔRBD) association with EBNA1. Approximately 2% of EBNA1 associated with FNCL, FNCLΔN, or ΔC, whereas EBNA1 did not bind to FNCL ΔRBD, which lacks the four RNA recognition motifs between amino acids 270 and 650 (Fig. 1F ). These data indicate that NCL RBDs and EBNA1 residues 1-99 are necessary for EBNA1 and NCL association.
Biomolecular fluorescence complementation assays revealed yellow fluorescent complexes in BJAB cells cotransfected with YN-NCL and YC-EBNA1Δ100-377, but not in cells cotransfected with YN-NCL and YC-EBNA1Δ1-377 ( Fig. S2 B and D) . YN and YC vectors expressed the expected fusion proteins when transfected into cells (Fig. S2C ). These data indicate that EBNA1 amino acids 1-99 and the NCL RBDs are necessary for EBNA1 interaction with NCL.
EBNA1 and NCL Colocalize in Nuclear Bodies. EBNA1 and NCL intracellular localizations were evaluated by confocal immune fluorescence microscopy by using BJAB B-lymphoma cells transfected with expression vectors for EGFP-EBNA1 and/or DsRed-NCL (Fig. S2A ). EGFP-EBNA1 or DsRed-NCL individually localized in multiple nuclear bodies. When expressed together in BJAB cells, EGFP-EBNA1 and DsRed-NCL colocalized, indicating that EBNA1 and NCL extensively associate with overlapping nuclear bodies. (Fig. S2A, Top) . Similar results were found in BJAB-FEBNA1 or IB4 LCLs by immunofluorescence with anti-EBNA1 and NCL antibodies (Fig. S2A , Lower). These data indicate that EBNA1 and NCL extensively colocalize in multiple nuclear bodies in BJAB cells and LCLs.
NCL Up-Regulates EBNA1-oriP-Mediated Transcription. Because NCL is implicated in Pol I-and Pol II-dependent transcription, we investigated whether increased NCL would increase EBNA1-induced oriP-SV40-Luc activity. EBNA1 activated oriP-SV40-Luc activity ∼17 fold (Fig. S3A ). Although FNCL expression vector increased NCL levels, neither oriP-SV40-Luc activity nor EBNA1 levels were affected by FNCL expression. However, FNCL expression with EBNA1 increased EBNA1 and oriP-dependent SV40-Luc expression from 17-fold to 30-to 50-fold, without increased EBNA1 expression (Fig. S3A ). These data indicate that increased NCL levels can significantly increase EBNA1 induced oriP-dependent-SV40-Luc expression.
To investigate NCL domains necessary for augmenting EBNA1 and oriP-dependent transcription, FNCL, FNCLΔN, FNCLΔC, or FNCLΔRBD were expressed with EBNA1 and EBNA1-oriP-SV40-luciferase activities were assessed ( activity 2.2 fold, whereas ΔN and ΔC had only 1.7 and 1.9-fold effects, and ΔRBD had the least affect. These results point to a specific role for the NCL RBD domain in NCL affects on EBNA1 and oriP-dependent transcription.
To further investigate NCL's role in EBNA1-mediated oriP-SV40-Luc transcription, BJAB cells were transduced with a lentivirus-expressing short hairpin (sh) NCL1 or shNCL2, or a scrambled control, shC, which did not alter NCL expression ( Fig.  2A) . In BJAB cells, shNCL1 and shNCL2 reduced NCL expression 84% and 66%, respectively, without altering EBNA1 levels (Fig. 2B) . EBNA1 activated oriP-SV40-Luc ∼12-fold in shC BJAB cells, whereas EBNA1-activated oriP-SV40-Luc minimally in shNCL1 BJAB cells and only slightly higher in shNCL2 BJAB cells. These data indicate that NCL is critical for EBNA1 up-regulation of an oriP-dependent luciferase reporter (Fig. 2B,  Left) . In contrast, an EBNA1-independent SV40 enhancer-and promoter-driven luciferase reporter plasmid was unaffected by NCL depletion (Fig. 2 B and C) .
As an additional control, the effect of an NPM knockdown was compared, NPM is an NCL-like histone chaperone that has multiple activities (28) . EBNA1-dependent oriP-SV40-luciferase activity in BJAB cells was not affected by NPM knockdown (Fig.  2D ), indicating that NPM is not important for EBNA1 and oriPdependent transcription.
NCL Is Essential for EBNA1 Binding to oriP and Episome Maintenance.
A streptavidin-agarose pulldown assay (SAPA) (29) was used to assess whether NCL is important for EBNA1 binding to biotinlabeled oriP-DNA (Fig. 3A, Left) . Indeed, ∼2% of EBNA1 was associated with biotin labeled oriP-DNA from BAJB FEBNA1 cells. No EBNA1 was associated with negative control LMP1 promoter DNA (Fig. 3A, Right) . ShNCL1 and 2 depleted NCL by 90% and 53%, respectively (Fig. 3A, Left) , whereas shC had no effect. EBNA1 from shC-transduced BJAB-FEBNA1 cells remained bound to oriP-DNA, whereas shNCL1 or shNCL2 eliminated or substantially decreased FEBNA1 binding to oriP and oriP-SV40-Luc. EBNA1 ChIP followed by qPCR was used to determine EBNA1-oriP binding. NCL knockdown almost abolished EBNA1 oriP binding, but had no effect on H3Ac ChIP-qPCR. (C) NCL knockdown reduced EBV DNA qPCR in LCLs but not in IB4 LCLs, which have only integrated EBV DNA. NCL shRNA (N1 or N2) depleted NCL in LCLs#1 and LCL#2 and IB4 LCLs. EBV genomes were quantitated by qPCR normalized to GAPDH genomic DNA. Untreated cells were set at 1. EBNA1, NCL, and actin loading controls were determined by Western blot.
DNA (Fig. 3A, Right) . These data indicate that EBNA1 binding to oriP DNA is NCL dependent. Also indicative of an important NCL role in EBNA1 binding to oriP, an EBNA1 ChIP brought down ∼8% of oriP-SV40-Luc reporter plasmid DNA from BJAB-FEBNA1-oriP-SV40-Luc reporter cells and from shC cells, but almost no oriP-SV40-Luc DNA was brought down from shNCL1 or shNCL2 cells. In contrast, control H3ac ChIP-seq brought down ∼9% of GAPDH promoter DNA and was unaffected by NCL depletion (Fig. 3B) . These data indicate that NCL is specifically required for EBNA1 binding to oriP DNA.
Because EBNA1 binding to oriP is necessary for EBV episome persistence, EBV genome persistence was monitored by quantitative real-time PCR (qPCR) following NCL depletion in LCL1 and LCL2, in which EBV DNA is episomal, and in IB4 cells, which have only integrated EBV DNA (30, 31) . EBV DNA in NCL-depleted LCL1 and LCL2 decreased 75-80% over 5 d (Fig.  3C , Left and Center), whereas NCL knockdown in IB4 cells did not affect EBV DNA levels (Fig. 3C, Right) . These data indicate that NCL is required for EBNA1 and oriP-based EBV episome maintenance.
NCL Is Essential for LCL Growth. Because NCL is necessary for EBV episome maintenance and gene expression, NCL was likely to be necessary for EBV conversion of primary B cells to LCLs. This hypothesis was first assessed in IB4 LCLs because the EBV genome is integrated in IB4 LCLs and EBNA1 is not necessary for EBV genome persistence. IB4 cells were lentivirus transduced with doxycyline-inducible shNCL1 or shNCL2 and assessed for viability after doxycycline-induced NCL knockdown. Induced shNCL1 or shNCL2 IB4 cells had 25% and 15% of IB4 NCL levels, respectively, and this level was inadequate to sustain LCL growth (Fig. S4 B-F) . These data indicate that IB4 LCL growth is NCL dependent.
NCL ATP Binding Is Important for EBNA1-oriP-Luc Activation. NCL is an ATP-binding protein (32) that affects protein-protein and protein-nucleic acid interactions relevant to ribosomal and mRNA transcription, transport, and stability (33) . ATP-agarose beads were used to evaluate the relative affinity of NCL versus EBNA1 for ATP. ATP-agarose bound ∼2% of NCL or EBNA1 (Fig. S5A) . FNCL, FNCLΔN, and FNCLΔC stably associated with ATP-agarose beads, whereas FNCL ΔRBD was deficient in ATP binding, confirming the importance of the NCL RNA recognition motifs in ATP binding (Fig. S5B) .
Antimycin A-mediated ATP depletion was used to evaluate the significance of ATP levels for NCL interaction with EBNA1 in IB4 cells. EBNA1 interaction with NCL in IB4 cells was Antimycin A inhibited (Fig. S5C) , indicating that ATP levels are critical for NCL interaction with EBNA1.
To further investigate the role of ATP in EBNA1-oriP-SV40-Luc activation, BJAB cells were treated with Antimycin A for 0.5, 1.5, or 2 h. Although FEBNA1 and actin levels were not altered by Antimycin A treament, EBNA1-oriP-SV40-Luc activity progressively decreased (Fig. S5D) . In contrast, enhancerless SV40p-Luc was unaffected by ATP depletion (Fig. S5E) . These results indicate that ATP levels are important for NCL and EBNA1 mediated-oriP-Luc activity, but not for SV40p-Luc. NCL has two predicted ATP binding sites separated by ∼180 residues in conserved RNA binding domains (32) . To assess the role of the putative NCL K429 and K610 ATP-binding sites in NCL effects, K429 and K610 were replaced with A429 or A610 (Fig. 4A) . Less predictable K624 and K627 NCL residues were replaced with alanine as control mutations less likely to affect NCL ATP binding. FNCL, K 429 A, K 610 A, and K 624/627 A were evaluated for ATP binding. K 610 A and K 624/627 A bound ATP similarly to FNCL, whereas K 429 A was deficient in ATP binding (Fig. 4B) . Co-IP analyses were used to evaluate the affect on EBNA1 interaction with FNCL. FNCL K 429 A, an ATP-binding null mutant and FNCL K 610 A, and K 624/627 A, which bind ATP, were evaluated for EBNA1 binding. FNCL, FNCL K 610 A, and K 624/627 A mutants efficiently bound EBNA1, whereas K 429 A was deficient in EBNA1 binding (Fig. 4C) . These data support the hypothesis that NCL K 429 ATP binding is essential for EBNA1 interaction.
EBNA1 consistently activated oriP-SV40-Luc 22-fold, and FNCL, K 610 A, or K 624/627 A augmented EBNA1 activation of oriP-SV40-Luc twofold, as previously shown for NCL (Fig. 4D, Left and  Fig. S3A ). In contrast, the ATP-binding mutant, NCL K 429 A, did not increase EBNA1 effects. As expected, shNCL1 that targeted the NCL 3′UTR reduced EBNA1 oriP activation (Fig. 4D, Right) and cDNAs for wild-type FNCL or control NCL mutants that preserve ATP binding, K 610 A, or K 624/627 A augmented EBNA1 oriP-SV40-Luc, whereas the null ATP-binding mutant cDNA, K 429 A, did not increase EBNA1 effects on oriP-SV40-Luc activation (Fig. 4D, Right) . Importantly, FNCL K 610 A and K 624/627 A substantially increased EBNA1 oriP-SV40-Luc DNA binding, by ChIP-qPCR, whereas, the FNCL K 429 A ATP binding null mutant failed to increase EBNA1-oriP DNA binding (Fig. 4E) . These results indicate that EBNA1-oriP-SV40-Luc activity and DNA binding are NCL ATP binding dependent.
Discussion
The data presented here indicate that: (i) EBNA1 is significantly associated with NCL in EBV-infected or EBNA1-expressing B lymphocytes. The association is mediated by the EBNA1 N-terminal 99 aa and the NCL RBD, and not by DNA or RNA.
(ii) EBNA1 and NCL independently localize in nuclear bodies and colocalize in similar nuclear bodies. (iii) Increased NCL expression does not by itself activate oriP-dependent transcription, but significantly increases EBNA1 activation. NCL's RBD is particularly important for increased EBNA1 effects. (iv) NCL shRNA knockdown substantially and specifically reduced EBNA1-oriPdependent transcription without affecting SV40 promoter-mediated transcription, revealing an NCL requirement for EBNA1-enhanced binding to oriP DNA and transcription, substantially decreased EBV DNA in LCLs, and inhibited the LCL growth. (v) EBNA1 and NCL had similar affinity for ATP-agarose beads. Antimycin A-mediated ATP depletion inhibits EBNA1 interaction with NCL, and substantially decreased EBNA1-oriP-dependent transcription, whereas an NCL ATP binding site point mutant is unable to increase EBNA1 binding to oriP DNA or EBNA1-oriP-dependent transcription. Thus, EBNA1 effects on oriPdependent transcription, DNA replication, and episome segregation to progeny cells requires NCL, making NCL an important target for inhibition of EBNA1 effects. EBNA1 Δ1-377 has been characterized as a defective mutant in transactivation and plasmid maintenance (12) , whereas functional characterization of EBNA1 Δ100-377 has not been reported. Although EBNA1 Δ100-377 is efficient in NCL binding, this mutant is expected to be defective in transactivation and plasmid maintenance because EBNA1 amino acids 325-376 are essential for transactivation and plasmid maintenance Although the crystal structure of EBNA1 bound to oriP DNA is solved at 2.4 A (13), compound screening has not identified a tool compound that disrupts the 1 M salt stable EBNA1 dimer on DNA (35) . Indeed, much was also known about EBNA1 interactions with chromatin that mediate oriP-DNA retention, transcription, and postmitotic nuclear segregation, much of which is mediated by EBNA1 RGG interactions with chromatin that may also be NCL dependent (for review, see ref. 1). Consequently, EBNA1 protein-protein interactions continue to identify strategies to inhibit EBNA1-mediated EBV genome maintenance or transcription in EBV malignant cells. Indeed, an EBNA1 association with NPM, an NCL associated protein, was recently discovered (10). However, NPM knockdown studies described here indicate that NPM is not critical for EBNA1 effects in oriP binding or enhanced transcription.
From a different perspective, HSP90 inhibitors can kill LCLs. This surprising cell death effect is likely due to a synthetic lethal effect of HSP90 inhibition on the EBNA1 Gly-Ala repeat domain interaction with infected cell proteasomes (36) . Consideration has also been given to potentially unique protein interactions that arise from EBNA1 recruitment of Cdc6, ORC, and MCM to oriP DNA complexes for EBV episome replication (16, 34, 37, 38) . EBNA1 also interacts with USP7 and guanosine 5′ monophosphate synthetase to form a complex with DNA to promote EBNA1 oriP-binding (18, 39) .
NCL may be an attractive therapeutic target because it is expressed at high levels in many cell types, including B lymphocytes, where it affects class switching. NCL is also implicated in CMV UL44-mediated DNA replication, in HSV1 UL12-mediated nucleocapsid egress (40, 41) , and in HPV18, but not HPV16, E6, and E7 transcription in cervical cancer (42) . Nucleolin also has important effects in cancer cell binding and stabilization of Hif-1α mRNA through ARE interactions (43) . Surface nucleolin can also protect B cells from Fas ligand-induced cell death (35) . Most recently, nucleolin has been found to posttranscriptionally up-regulate mir-21, mir-221, mir-222, and mir-103 in breast cancer initiation, progression, and drug resistance (44) . NCL may be involved in EBNA1-mediated transcription through interactions with other chromatin remodelers, such as SWI/SNF or ATP-dependent chromatin remodeling factor (ACF) complexes.
Although the mechanisms by which NCL promotes nucleosome remodeling remain to be elucidated, the ability of NCL to increase H2A-H2B dimer turnover may be important in NCL Pol II-dependent transcription (22) . EBNA1 recruitment of H2B-USP7 deubiquitylating complexes has been implicated in EBNA1-oriP binding (39) .
The importance of NCL in EBNA1 interactions with oriP opens an opportunity for targeting EBNA1 interactions with NCL in all cell types, although the effects may be more evident in B cells. Given the complex role of NCL in breast cancer, compounds that target NCL RBDs may be of therapeutic potential for EBV and other malignancies (44) .
Materials and Methods
Large-Scale Immunoprecipitation and LC-MS/MS Analyses. BJAB-FEBNA1 or control BJAB cells (1 × 10 9 ) were lyzed and subjected to immune precipitation by using M2-Sepharose beads. The precipitated proteins were resolved on a 4-20% gradient gel. FEBNA1-associated cellular proteins were visualized by Coomassie blue staining. The specific bands were excised and subjected to LC-MS/MS analyses (Protech Taiwan).
NCL Lentivirus shRNA Knockdown. Lentiviral plasmids containing NCL or scrambled shRNA were purchased from the National RNAi Core Facility, Academic Sinica Taiwan. For NCL depletion, 5 × 10 5 BJAB, IB4, or wild-type LCL cells were transduced with 1 mL of the lentiviral supernatants in the presence of 8 μg/mL polybrene. Forty-eight hours later, the cells were treated with 5 ng/mL puromycin.
Chromatin Immunoprecipitation and qPCR. After cross-linking with 1% formaldehyde, the cells were lyzed. The lysates were subjected to immune precipitation with antibodies against EBNA1 (6F9/60; Novas Biologicals), acetyl-H3 (H3ac) and IgG control (Millipore). Following extensive wash, DNA was purified. Precipitated DNA was determined by qPCR with primers for oriP or GAPDH. Detailed materials and methods are available SI Materials and Methods.
